The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Evinova will operate as a separate health-tech business within AstraZeneca
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
he company posted total income during Q2 FY24 at Rs. 12.86 crore
US business grew by +12.8% YoY
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Total transaction value of the divestment is Rs. 3,660 million
RHTC will address a long-standing healthcare access issue for all the local population
Subscribe To Our Newsletter & Stay Updated
